Evolution of resistance to KRAS<sup>G12C</sup> inhibitor in a non-small cell lung cancer responder

Jiahui Xu; Shijia Wang; Ziming Wang; Jumin Huang; Chun Xie; Tingting Zhao; Yuqing Niu; Yabing Cao; Chen Ming; Elaine Lai-Han Leung

doi:10.1016/j.jgg.2026.07.002

Turn off MathJax

Article Contents

Article Navigation > Journal of Genetics and Genomics > 2026 > Accepted Manuscript

PDF( 0 KB)

Evolution of resistance to KRAS^G12C inhibitor in a non-small cell lung cancer responder

doi: 10.1016/j.jgg.2026.07.002

Jiahui Xu^a,b,c,
Shijia Wang^a,b,d,
Ziming Wang^a,b,
Jumin Huang^a,b,
Chun Xie^a,b,
Tingting Zhao^a,b,
Yuqing Niu^a,b,
Yabing Cao^e,
Chen Ming^a,b,d,f,
Elaine Lai-Han Leung^a,b,c

a. Cancer Center, Faculty of Health Sciences, University of Macau, Macau SAR 999078, China;
b. MOE Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR 999078, China;
c. State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Macau SAR 999078, China;
d. Department of Public Health and Medicinal Administration, Faculty of Health Sciences, University of Macau, Macau SAR 999078, China;
e. Cancer Center, Kiang Wu Hospital, Macau SAR 999078, China;
f. Centre for Cognitive and Brain Sciences, University of Macau, Macao SAR 999078, China

Funds:

This work was funded by regular grants (0063/2022/A2) supported by the Macau Science and Technology Development Fund. This work is also financially supported by the Start-up Research Grant of University of Macau (SRG2022-00020-FHS, SRG2023-00003-FHS), the 2023 State Key Laboratory of Quality Research in Chinese Medicine (UM) Internal Research Grant (IRG) (SKL-QRCM-IRG2023-001), and the FSCPO project (type 1) from Faculty of Health Science, University of Macau. This work is also financially supported by the Science and Technology Development Fund Macau SAR (005/2023/SKL, 0040/2025/ITP1, 0010/2023/AKP), and the joint FDCT-NSFC grant (0145/2025/AFJ).

Received Date: 2026-01-14
Accepted Date: 2026-07-06
Rev Recd Date: 2026-07-01

Available Online: 2026-07-11

Abstract

FullText(HTML)

References(20)

References

Aibar, S., Gonzalez-Blas, C.B., Moerman, T., Huynh-Thu, V.A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.C., Geurts, P., Aerts, J., et al., 2017. Scenic: Single-cell regulatory network inference and clustering. Nat. Methods 14, 1083-1086.

Awad, M.M., Liu, S., Rybkin, II, Arbour, K.C., Dilly, J., Zhu, V.W., Johnson, M.L., Heist, R.S., Patil, T., Riely, G.J., et al., 2021. Acquired resistance to KRASG12C inhibition in cancer. N. Engl. J. Med. 384, 2382-2393.

de Langen, A.J., Johnson, M.L., Mazieres, J., Dingemans, A.C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., et al., 2023. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: A randomised, open-label, phase 3 trial. Lancet 401, 733-746.

Du, W., Nair, P., Johnston, A., Wu, P.H., Wirtz, D., 2022. Cell trafficking at the intersection of the tumor-immune compartments. Annu. Rev. Biomed. Eng. 24, 275-305.

Germain, C., Meier, A., Jensen, T., Knapnougel, P., Poupon, G., Lazzari, A., Neisig, A., Hakansson, K., Dong, T., Wagtmann, N., et al., 2011. Induction of lectin-like transcript 1 (llt1) protein cell surface expression by pathogens and interferon-gamma contributes to modulate immune responses. J. Biol. Chem. 286, 37964-37975.

Hallin, J., Engstrom, L.D., Hargis, L., Calinisan, A., Aranda, R., Briere, D.M., Sudhakar, N., Bowcut, V., Baer, B.R., Ballard, J.A., et al., 2020. The KRASG12C inhibitor mrtx849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer. Discov. 10, 54-71.

Huang, D., Yin, J., Zou, Y., Huang, H., Long, S., Sun, W., Du, J., Fan, J., Peng, X., 2024. A self-reinforced activatable photosensitizer prodrug enabling synergistic photodynamic and chemotherapy. Smart. Mol. 2, e20240005.

Jin, S., Guerrero-Juarez, C.F., Zhang, L., Chang, I., Ramos, R., Kuan, C.-H., Myung, P., Plikus, M.V., Nie, Q., 2021. Inference and analysis of cell-cell communication using cellchat. Nat. Commun. 12, 1088.

Leung, E.L., Li, R.Z., Fan, X.X., Wang, L.Y., Wang, Y., Jiang, Z., Huang, J., Pan, H.D., Fan, Y., Xu, H., et al., 2023. Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy. Nat. Commun. 14, 5115.

Liu, D., Lin, J.R., Robitschek, E.J., Kasumova, G.G., Heyde, A., Shi, A., Kraya, A., Zhang, G., Moll, T., Frederick, D.T., et al., 2021. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nat. Med. 27, 985-992.

Pauken, K.E., Shahid, O., Lagattuta, K.A., Mahuron, K.M., Luber, J.M., Lowe, M.M., Huang, L., Delaney, C., Long, J.M., Fung, M.E., et al., 2021. Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment. J. Exp. Med. 218, e20200920.

Pesaresi, M., Bonilla-Pons, S.A., Sebastian-Perez, R., Di Vicino, U., Alcoverro-Bertran, M., Michael, R., Cosma, M.P., 2021. The chemokine receptors CCR5 and CXCR6 enhance migration of mesenchymal stem cells into the degenerating retina. Mol. Ther. 29, 804-821.

Pi, Z., Liu, W., Song, C., Zhu, C., Liu, J., Wang, L., He, Z., Yang, C., Wu, L., Liu, T., et al., 2024. Multi-level insights into the immuno-oncology-microbiome axis: From biotechnology to novel therapies. Imeta 3, e240.

Reck, M., Carbone, D.P., Garassino, M., Barlesi, F., 2021. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann. Oncol. 32, 1101-1110.

Ryan, M.B., Fece de la Cruz, F., Phat, S., Myers, D.T., Wong, E., Shahzade, H.A., Hong, C.B., Corcoran, R.B., 2020. Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition. Clin. Cancer. Res. 26, 1633-1643.

Van de Sande, B., Lee, J.S., Mutasa-Gottgens, E., Naughton, B., Bacon, W., Manning, J., Wang, Y., Pollard, J., Mendez, M., Hill, J., et al., 2023. Applications of single-cell rna sequencing in drug discovery and development. Nat. Rev. Drug. Discov. 22, 496-520.

Wei, Y., Xu, T., Li, C., Zhou, X., Qian, W., Shen, C., Wang, Q., Xing, X., Ou, X., He, X., et al., 2023. CD161 characterizes an inflamed subset of cytotoxic T lymphocytes associated with prolonged survival in human papillomavirus-driven oropharyngeal cancer. Cancer. Immunol. Res. 11, 306-319.

Xie, X., Liu, W., Yuan, Z., Chen, H., Mao, W., 2025. Bridging epigenomics and tumor immunometabolism: molecular mechanisms and therapeutic implications. Mol. Cancer 24, 71.

Zheng, R., Zhang, S., Zeng, H., Wang, S., Sun, K., Chen, R., Li, L., Wei, W., He, J., 2022. Cancer incidence and mortality in china, 2016. J. Natl. Cancer. Cent. 2, 1-9.

Zheng, Y., Lai, Q., Zhao, H., Li, X., Sun, X., Xing, L., 2021. Clinical characteristics and outcomes of chinese patients with kras-mutant non-small cell lung cancer after chemotherapy. Cancer. Commun. (Lond) 41, 1234-1238.

Relative Articles

Supplements(0)

Cited By

Proportional views